PubRank

Clinical Medicine Insights. Oncology (Clin Med Insights Oncol)

Journal PubWeight™ 149.48‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Bevacizumab for the treatment of recurrent glioblastoma. 2011 1.24
2 Cancer-associated thrombosis: an overview. 2014 1.23
3 Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer. 2013 1.19
4 Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. 2014 1.17
5 Vandetanib for the treatment of metastatic medullary thyroid cancer. 2012 1.15
6 Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. 2010 1.13
7 Advanced Extramammary Paget's Disease of the Groin, Penis, and Scrotum. 2014 1.08
8 Survival of patients with squamous cell malignancies of the upper urinary tract. 2011 1.07
9 High Dose Rate Brachytherapy in the Treatment of cervical cancer: preliminary experience with cobalt 60 Radionuclide source-A Prospective Study. 2010 1.04
10 Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma. 2011 1.00
11 Primary Extra-gastrointestinal Stromal Tumor of Retroperitoneum. 2012 1.00
12 A study of aspects on gender and prognosis in synchronous colorectal cancer. 2011 0.98
13 Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. 2013 0.95
14 Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML. 2011 0.93
15 Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. 2012 0.93
16 Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. 2011 0.92
17 Small cell lung cancer doubling time and its effect on clinical presentation: a concise review. 2012 0.91
18 Aflibercept in the treatment of metastatic colorectal cancer. 2012 0.91
19 Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy. 2015 0.90
20 Bevacizumab for the treatment of glioblastoma. 2013 0.90
21 Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. 2013 0.90
22 Renal cell carcinoma: focus on safety and efficacy of temsirolimus. 2010 0.90
23 Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information. 2014 0.89
24 Paclitaxel as neoadjuvant therapy for high grade angiosarcoma of the spleen: a brief report and literature review. 2010 0.89
25 A six-year study of the clinical presentation of cervical cancer and the management challenges encountered at a state teaching hospital in southeast Nigeria. 2013 0.89
26 The Importance of Multidisciplinary Approach in Early Detection of BAP1 Tumor Predisposition Syndrome: Clinical Management and Risk Assessment. 2014 0.89
27 Review of the treatment of non-small cell lung cancer with gefitinib. 2012 0.88
28 Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide. 2011 0.87
29 The role of T lymphocytes in cancer patients undergoing immunotherapy with autologous dendritic cells. 2011 0.87
30 Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia. 2014 0.87
31 Pilot study of a clinical pathway implementation in rectal cancer. 2010 0.87
32 Obesity Correlation With Metastases Development and Response to First-Line Metastatic Chemotherapy in Breast Cancer. 2015 0.87
33 Current and emerging treatment options for patients with relapsed myeloma. 2013 0.86
34 A case of late-onset gemcitabine lung toxicity. 2011 0.86
35 Three Cases of Combined Therapy in Primary Breast Lymphoma (PBL) with Successful Outcomes. 2013 0.85
36 Transgenic and knockout mice models to reveal the functions of tumor suppressor genes. 2011 0.85
37 Nelarabine in the treatment of refractory T-cell malignancies. 2010 0.85
38 Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin. 2012 0.84
39 Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment. 2014 0.84
40 A De Novo Germline APC Mutation (3927del5) in a Patient with Familial Adenomatous Polyposis: Case Report and Literature Review. 2012 0.84
41 The use of patient navigators to improve cancer care for Hispanic patients. 2011 0.84
42 Intraperitoneal follicular dendritic cell sarcoma: role of chemotherapy and bone marrow allotransplantation in locally advanced disease? 2015 0.83
43 Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. 2016 0.83
44 Folate Levels and Polymorphisms in the Genes MTHFR, MTR, and TS in Colorectal Cancer. 2014 0.83
45 Targeted therapies in the treatment of advanced hepatocellular carcinoma. 2013 0.83
46 C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin. 2013 0.83
47 Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice. 2016 0.82
48 Spinal osteosarcoma. 2013 0.82
49 The Prognostic Role of the Neutrophil-to-Lymphocyte Ratio in Oropharyngeal Carcinoma Treated with Chemoradiotherapy. 2014 0.82
50 Primary monophasic synovial sarcoma of the kidney: a case report and review of literature. 2013 0.82
Next 50